CareDx, Inc. is a precision medicine diagnostics company focused on transplant care and related specialty services. CareDx develops and commercializes non-invasive molecular tests, laboratory products, digital tools, and patient support services that help clinicians monitor organ health before and after transplantation. Its portfolio includes testing solutions for kidney, heart, and lung transplant patients, along with HLA typing and other transplant laboratory products used to support donor-recipient matching and post-transplant surveillance. The company also offers workflow software, data analytics, and care-management tools that connect transplant centers, patients, and providers across the care journey. In addition to its core transplant business, CareDx serves specialty oncology and cell therapy markets with precision diagnostics and support solutions. CareDx, Inc. is headquartered in Brisbane, California.
Website8000 Marina Boulevard
Brisbane, CA, 94005
United States
CareDx has staged a dramatic turnaround, resolving Medicare risk, returning to profitability, and initiating share buybacks. Read more on CDNA stock here.
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) is up about 14% today after BTIG raised its price target from $60 to $74 and maintained its Buy rating. That’s a big move for a target bump – and there may be even more upside to be had… The detailsBTIG hosted CareDx’s CEO, CFO, and head of investor relations for investor meetings in Boston earlier this week, and came away more bullish: Target raised 23%, from $60 to $74Management sounded confident after the positive resolution of the transplant local coverage determination (this i
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
Investors talking about CDNA also mention
| # | Name | Attention |
|---|---|---|
| 1 | Natera, Inc.NTRA | 0%-0.01 |
| 2 | Veracyte, Inc.VCYT | 0%new |
| 3 | 10x Genomics Inc. Class A Common StockTXG | 0%-0.02 |
| 4 | Castle Biosciences Inc.CSTL | 0%new |
| 5 | Guardant Health Inc.GH | 0%-0.11 |
| 6 | Fortrea Holdings Inc.FTRE | 0%0 |
| 7 | Dianthus Therapeutics Inc.DNTH | 0%0 |
| 8 | Vestis CorporationVSTS | 0%new |
| 9 | Integra LifeSciences Holdings CorporationIART | 0%0 |
| 10 | Bruker CorpBRKR | 0%0 |
What share of all stock conversation is about CDNA?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0.01% +0.01 | 0.01% +0 | 0% +0 | 0% +0 |
Of the messages about CDNA that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% | 95.41% -3.1 | 97.4% +31.61 | 87.14% -1.69 | ||
| Bearish | 0% | 4.59% +3.1 | 2.6% -31.61 | 12.86% +1.69 |
Of the messages about CDNA that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Technical Analysis | 100% | 93.24% | 90.38% | 50.06% | ||
| Announcements | 0% | 5.41% | 6.73% | 42.33% | ||
| Analysts | 0% | 1.35% | 2.88% | 3.14% | ||
| Earnings | 0% | 0% | 0% | 4.48% | ||
| Controversies | 0% | 0% | 0% | 0% | ||
| Macro | 0% | 0% | 0% | 0% |
Of the messages about CDNA, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 83.53% | 46.77% | 66.22% | 55.1% | ||
| Newcomers | 16.47% | 53.23% | 33.78% | 44.9% |